Erythropoietic protoporphyria is a photodermatosis presenting in childhood with severe pain on sun exposure. The diagnosis is often delayed because of the lack of awareness among pediatricians. We describe the diagnostic odyssey of 2 children presenting with symptoms of erythropoietic protoporphyria and report results of a survey of 129 affected individuals. (J Pediatr 2018;202:320-3). E rythropoietic protoporphyria (EPP), an autosomal recessive photodermatosis, results from a deficiency of ferrochelatase, the last enzyme in the heme biosynthetic pathway (Figure 1 ; available at www.jpeds.com), because of mutations in the FECH gene.
1
EPP is the most common porphyria in children and prevalence estimates range from 1:200 000 to 1:75 000. 1 Patients develop severe, nonblistering phototoxicity within minutes of sun exposure. 3, 4 The pain is usually described as 10 on the pain scale. Most individuals with EPP experience tingling, itching, and burning of the skin preceding the pain, followed by swelling and redness of sun-exposed areas. These prodromal symptoms serve as a warning sign to end sun exposure. Over time, patients develop a conditioned behavior of sun avoidance, which markedly limits their quality of life. [5] [6] [7] Symptoms are preventable by sun avoidance through the use of protective clothing, shade, and tinted windows. These episodes can last up to 7 days, causing missed school or work. Severity is highly variable, however, most patients are able to tolerate <30 minutes of sun exposure. 5 With chronic exposure, the involved skin may become hyperkeratotic. 3, 8 Anemia is seen in~40% of patients and 25% of patients will develop abnormal serum aminotransferases. 1, 4 Approximately 2%-5% of patients develop clinically significant liver dysfunction attributable to protoporphyrin deposition in bile and/or hepatocytes that can advance to cholestatic liver failure requiring transplantation. There is an increased risk of gallstones, which may present at a younger age. 5 The diagnosis of EPP is made by detection of markedly increased erythrocyte protoporphyrin levels with a predominance of metal-free protoporphyrin. Plasma total porphyrins are also increased. 1, 5 In other erythrocyte disorders such as lead poisoning and anemia, the excess protoporphyrin accumulates mostly as zinc protoporphyrin. Genetic testing by sequencing the FECH or ALAS2 gene confirms the diagnosis. 1, 2 Clinical trials have shown that afamelanotide, a synthetic analog of a-melanocyte stimulating hormone, increased painfree sun exposure and improved quality of life in adults with EPP. 4, 6, 9, 10 It has been approved for use in the European Union since 2014 and is currently being evaluated by the US Food and Drug Administration. Other therapies, such as beta carotene and cimetidine have not conclusively been proven to be effective for symptomatic management.
11,12
Here we report 2 children with EPP, with a prolonged diagnostic odyssey. We highlight the challenges of identifying this rare, but important, disease that affects quality of life, not only for the patient, but also their families.
Patient 1
A 2-year-old white male child presented to an urgent care clinic in severe pain, with swelling of the hands and feet after spending several hours at a lake with his family; his symptoms were initially thought to be an allergic reaction to the lake water, the sand, or his sunscreen. The swelling continued overnight, and the next day he was brought to the local emergency department where his symptoms were attributed to geese feces exposure; he was given a dose of prednisone and discharged. The swelling and pain worsened, causing insomnia over the next several days. The symptoms subsided without additional intervention 4 days after onset.
The following summer, at age 3 years, he had 2 similar episodes while swimming and was given diphenhydramine without relief. During these episodes, he was noted to have intense itching of his skin. He was evaluated by a pediatrician, who discharged him without further testing or recommendations. 
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One year later, he was noted to have swelling of his hands and feet after spending time in a pool. He was inconsolable, with intense itching and redness on his extremities. (Figure 2 , A). He was brought to the local emergency department, where he was given a dose of prednisone and discharged. After this episode, his family noted that he was hesitant to spend time outdoors and would seek shade whenever possible. He was evaluated by his pediatrician, who attributed his symptoms to a sunscreen allergy and referred him to a pediatric dermatologist, who recommended no further intervention. He then saw an allergist, who had no recommendations. A second pediatrician referred him to another pediatric dermatologist who ordered protoporphyrin testing, finally diagnosing EPP (Table I) .
At 12 years of age, he continues to use photoprotection and minimizes sun exposure as the mainstay of his management. Currently, he experiences symptoms within 5 minutes of sun exposure.
Patient 2
A 5-year-old white female child was noted to have pain with itching, burning, and swelling on her hands and feet after 1 day on the beach; her symptoms were refractory to various antihistamines and resolved without intervention after 1 week. She was seen by a pediatrician who prescribed prednisone, without relief, and a dermatologist. Both suspected a seafood allergy or idiopathic angioedema. She experienced similar symptoms 1 year later again at the beach. At that time, her pediatrician performed bloodwork, which showed a speckled antinuclear antibody pattern, and she was referred to a pediatric rheumatologist, where her workup was negative. She was also referred to an allergist, where skin testing was negative. During this time, she found relief from avoidance of sun exposure and the use of photoprotective clothing.
At 7 years of age, she went to summer camp and noted scabbing on the tip of her nose in addition to swelling, redness, itching, and burning of her hands, arms and face (Figure 2 , B and C). This resolved without intervention after 5 days. A consultation with a dermatologist suggested the possibility of a diagnosis of EPP, but no testing was ordered as it was considered unlikely. Shortly after, her mother watched a television show featuring EPP and requested the dermatologist perform laboratory testing, which confirmed the diagnosis of EPP (Table I) .
She is now 11 years of age and reports that her symptoms continue to be worse during the spring and summer. Currently, her symptoms include tingling, burning, and swelling of her face, hands, and feet that last up to 4 days; they are not alleviated by any interventions. 
Results
To evaluate the diagnostic delay in the US, we surveyed individuals through an anonymous online survey administered through the American Porphyria Foundation listserv and social media platform. This study was determined to be exempt by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai. Eighty-eight (68%) adults with EPP and 41 (32%) parents of a child with EPP completed the survey. The majority (76%) presented with symptoms of EPP before 4 years of age (Figure 3 ; available at www.jpeds.com). This is consistent with a previous report of US patients 5 ; 70% of patients saw their pediatrician or primary healthcare provider for symptoms, and 44% first saw a pediatric subspecialist; allergy/immunology and dermatology were the most commonly seen (Table II ; available at www.jpeds.com). The mean number of years between initial symptoms and diagnosis of EPP was 13 years (Figure 3) . In 43% of total patients, a dermatologist suggested the diagnosis of EPP; a pediatric dermatologist suggested the diagnosis in 7% of cases (Table III ; available at www.jpeds.com). Thirtyeight percent of patients saw 5 or more physicians prior to being diagnosed with EPP; of those, 22% saw more than 10 physicians. In 15% of cases, our respondents suggested the diagnosis of EPP to their physician; 16% first heard about EPP through the media. Prior to diagnosis, the majority of individuals were thought to have a sun allergy (50%), or another type of allergic reaction (16%); 15% of individuals were thought to have a psychological issue. A limitation of our study includes the lack of medical confirmation of the diagnosis. However, patients and family members are prescreened by the APF before joining these groups.
Discussion
Previous studies in Europe have shown a significant diagnostic delay for patients with EPP. Holme et al identified 389 patients with EPP in the United Kingdom; the median ages at symptom onset and diagnosis were 1 and 12 years, respectively. 3 Wahlin et al identified 51 patients with EPP in Sweden; the median ages at onset and diagnosis were 1 and 22 years. 13 Our data and previous reports suggest that the diagnostic delay can be over a decade. 3, 13 Difficulties in making the diagnosis include the lack of cutaneous lesions in between attacks and the absence of abnormalities on routine laboratory studies. In addition, protoporphyrin testing needs to be sent to a specialty laboratory for an accurate diagnosis. 10 Skin biopsy is not diagnostic as the findings are nonspecific. 14 Early diagnosis can lead to benefits of decreasing sun exposure and appropriate follow up including monitoring for hepatic complications which, though rare, can present in childhood requiring liver and/or bone marrow transplantation. 15 Recommended annual monitoring includes erythrocyte protoporphyrin levels, hepatic function, hematologic indices, an iron profile, and 25-hydroxy vitamin D levels (Table IV; available at www.jpeds.com). 1 In addition, early diagnosis of EPP is important for management, particularly as newer therapies such as afamelanotide may reach market authorization. Although there is limited published data on the psychosocial effects in children, a recent focus group study suggests that this disorder has a significant impact on children. 8 We conclude that there is a need for educating pediatric providers about EPP to prevent a delay in diagnosis in children with phototoxicity, allowing for enhanced quality of life. ■ Figure 1 . Heme biosynthetic pathway. In EPP, biallelic mutations in FECH lead to the deficiency of ferrochelatase, the last enzyme of the heme-biosynthetic pathway resulting in the accumulation of protoporphyrin. In X-linked protoporphyria, a gain-of-function mutation in ALAS2 results in more protoporphyrin than is required for hemoglobinization and it accumulates despite the normal ferrochelatase activity. ) ; respondents who reported that they suggested the diagnosis to a physician or had a family history of EPP (n = 36) were excluded. †Includes both dermatologists (n = 37) and pediatric dermatologists (n = 9). ‡One respondent indicated that a pediatric dermatologist and a geneticist suggested the diagnosis of EPP. 
